- Home
- BXP vs EXAS Comparison
BXP vs EXAS Comparison
Compare BXP & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXP
- EXAS
- Stock Information
- Founded
- BXP 1970
- EXAS 1995
- Country
- BXP United States
- EXAS United States
- Employees
- BXP N/A
- EXAS N/A
- Industry
- BXP Real Estate Investment Trusts
- EXAS Medical Specialities
- Sector
- BXP Real Estate
- EXAS Health Care
- Exchange
- BXP Nasdaq
- EXAS Nasdaq
- Market Cap
- BXP 13.1B
- EXAS 11.6B
- IPO Year
- BXP 1997
- EXAS N/A
- Fundamental
- Price
- BXP $74.62
- EXAS $59.40
- Analyst Decision
- BXP Buy
- EXAS Strong Buy
- Analyst Count
- BXP 14
- EXAS 16
- Target Price
- BXP $81.07
- EXAS $72.80
- AVG Volume (30 Days)
- BXP 1.3M
- EXAS 2.3M
- Earning Date
- BXP 01-28-2025
- EXAS 11-05-2024
- Dividend Yield
- BXP 5.25%
- EXAS N/A
- EPS Growth
- BXP 87.61
- EXAS N/A
- EPS
- BXP 2.30
- EXAS N/A
- Revenue
- BXP $3,344,005,000.00
- EXAS $2,692,328,000.00
- Revenue This Year
- BXP N/A
- EXAS $11.81
- Revenue Next Year
- BXP $1.65
- EXAS $11.41
- P/E Ratio
- BXP $32.46
- EXAS N/A
- Revenue Growth
- BXP 4.47
- EXAS 11.91
- 52 Week Low
- BXP $56.46
- EXAS $40.62
- 52 Week High
- BXP $90.11
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- BXP 34.38
- EXAS 48.45
- Support Level
- BXP $72.70
- EXAS $55.65
- Resistance Level
- BXP $80.81
- EXAS $62.15
- Average True Range (ATR)
- BXP 2.21
- EXAS 2.41
- MACD
- BXP -0.71
- EXAS -0.26
- Stochastic Oscillator
- BXP 18.13
- EXAS 41.12
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.